0A8R

Seagen LSE:0A8R Stock Report

Last Price

US$138.21

Market Cap

US$25.6b

7D

-1.4%

1Y

-1.1%

Updated

06 Feb, 2023

Data

Company Financials +

0A8R Stock Overview

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally.

0A8R fundamental analysis
Snowflake Score
Valuation4/6
Future Growth5/6
Past Performance0/6
Financial Health5/6
Dividends0/6

My Notes

New

Notes are coming soon

Seagen Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Seagen
Historical stock prices
Current Share PriceUS$138.21
52 Week HighUS$181.87
52 Week LowUS$115.07
Beta0.57
1 Month Change1.92%
3 Month Change2.38%
1 Year Change-1.13%
3 Year Changen/a
5 Year Changen/a
Change since IPO-4.89%

Recent News & Updates

Recent updates

Shareholder Returns

0A8RGB BiotechsGB Market
7D-1.4%-0.05%1.8%
1Y-1.1%-24.7%-3.7%

Return vs Industry: 0A8R exceeded the UK Biotechs industry which returned -24.7% over the past year.

Return vs Market: 0A8R exceeded the UK Market which returned -3.7% over the past year.

Price Volatility

Is 0A8R's price volatile compared to industry and market?
0A8R volatility
0A8R Average Weekly Movement6.3%
Biotechs Industry Average Movement8.4%
Market Average Movement5.1%
10% most volatile stocks in GB Market11.0%
10% least volatile stocks in GB Market2.7%

Stable Share Price: 0A8R is not significantly more volatile than the rest of UK stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: 0A8R's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19972,675David Epsteinhttps://www.seagen.com

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases.

Seagen Inc. Fundamentals Summary

How do Seagen's earnings and revenue compare to its market cap?
0A8R fundamental statistics
Market CapUS$25.62b
Earnings (TTM)-US$636.76m
Revenue (TTM)US$1.86b

13.7x

P/S Ratio

-40.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
0A8R income statement (TTM)
RevenueUS$1.86b
Cost of RevenueUS$1.68b
Gross ProfitUS$184.76m
Other ExpensesUS$821.53m
Earnings-US$636.76m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

Feb 15, 2023

Earnings per share (EPS)-3.43
Gross Margin9.91%
Net Profit Margin-34.16%
Debt/Equity Ratio0%

How did 0A8R perform over the long term?

See historical performance and comparison